LYTAC platform
Drug discovery platformA lysosomal-targeting-chimera drug discovery platform that generates bifunctional molecules which bind an extracellular target protein and shuttle it into the lysosome for degradation, plus a catalytic variant the company calls CataLYTAC.
- Degrades extracellular and transmembrane proteins rather than merely inhibiting them
- CataLYTAC catalytic degrader modality
- Antigen-specific autoantibody degradation for autoimmune disease
- Founded on lysosomal targeting chemistry from the Bertozzi lab
